Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xencor Inc XNCR

Healthcare Biotechnology
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of... see more

Recent & Breaking News (NDAQ:XNCR)

Xencor's Partner Initiates Phase 2 Clinical Trial of a Biologic Candidate Using XmAb® Cytotoxic Fc Domain

PR Newswire September 24, 2015

Amgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And Inflammation

PR Newswire September 16, 2015

Xencor Reports Second Quarter 2015 Financial and Operating Results

PR Newswire August 4, 2015

Xencor to Present at 2015 Wedbush PacGrow Healthcare Conference

PR Newswire August 4, 2015

Xencor Appoints Yujiro S. Hata to Board of Directors

PR Newswire July 31, 2015

Xencor to Host Second Quarter 2015 Financial Results Webcast and Conference Call on August 4, 2015

PR Newswire July 28, 2015

Xencor Provides Update on Two Lead XmAb® Product Candidates and Expansion of Bispecific Oncology Pipeline at R&D Day

PR Newswire June 26, 2015

Xencor to Host R&D Day and Webcast on June 26, 2015

PR Newswire June 12, 2015

Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting

PR Newswire June 10, 2015

Xencor to Present at Jefferies 2015 Healthcare Conference

PR Newswire May 26, 2015

Xencor, Inc. Appoints Mark Lotz, R.Ph., as Vice President of Regulatory Affairs and Wayne Saville, M.D., as Vice President of Clinical Oncology

PR Newswire May 13, 2015

Xencor's XmAb®5871 Program to be Featured in Poster Presentation at European League Against Rheumatism (EULAR) 2015 Annual Meeting

PR Newswire May 11, 2015

Xencor Reports First Quarter 2015 Financial and Operating Results

PR Newswire May 4, 2015

Xencor to Webcast Presentations at Two Upcoming Conferences in May

PR Newswire April 29, 2015

Xencor to Host First Quarter 2015 Financial Results Webcast and Conference Call on May 4, 2015

PR Newswire April 28, 2015

Xencor Appoints A. Bruce Montgomery, M.D. to Board of Directors

PR Newswire March 19, 2015

Xencor to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

PR Newswire March 16, 2015

Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock

PR Newswire March 2, 2015

Xencor, Inc. Prices Public Offering of Common Stock

PR Newswire February 25, 2015

Xencor, Inc. Announces Proposed Public Offering of Common Stock

PR Newswire February 23, 2015